Wedbush Has Negative Estimate for argenex Q2 Earnings

Key Points

• Wedbush has revised its Q2 2026 EPS estimate for argenex to $6.18, down from a previous estimate of $6.23, while maintaining an "Outperform" rating and a price objective of $880.00.
• The consensus estimate for argenex's full-year earnings is currently $3.13 per share, with upcoming Q3 2026 earnings expected at $6.73 EPS.
• argonex has a market capitalization of $48.93 billion, with shares currently trading at $799.56, reflecting a 52-week range between $510.05 and $810.16.

argenex SE (NASDAQ:ARGX - Free Report) - Equities researchers at Wedbush cut their Q2 2026 EPS estimates for argenex in a research note issued to investors on Monday, October 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $6.18 per share for the quarter, down from their prior forecast of $6.23. Wedbush has a "Outperform" rating and a $880.00 price objective on the stock. The consensus estimate for argenex's current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex's Q3 2026 earnings at $6.73 EPS and FY2026 earnings at $25.75 EPS.

ARGX has been the topic of several other research reports. Weiss Ratings reiterated a "hold (c)" rating on shares of argenex in a research report on Wednesday, October 8th. Royal Bank Of Canada started coverage on shares of argenex in a research report on Monday, August 25th. They set an "outperform" rating and a $850.00 price target on the stock. Zacks Research upgraded shares of argenex from a "hold" rating to a "strong-buy" rating in a research report on Monday, September 22nd. Deutsche Bank Aktiengesellschaft downgraded shares of argenex from a "buy" rating to a "hold" rating in a research report on Thursday, September 11th. Finally, JPMorgan Chase & Co. boosted their price objective on argenex from $775.00 to $830.00 and gave the stock an "overweight" rating in a report on Monday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $817.53.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $799.56 on Tuesday. argenex has a 52 week low of $510.05 and a 52 week high of $810.16. The company's fifty day moving average is $722.14 and its 200-day moving average is $629.47. The company has a market capitalization of $48.93 billion, a PE ratio of 41.00, a P/E/G ratio of 0.86 and a beta of 0.46.

argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The firm had revenue of $866.79 million for the quarter, compared to the consensus estimate of $776.82 million.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC boosted its stake in argenex by 41.6% in the first quarter. Janney Montgomery Scott LLC now owns 1,141 shares of the company's stock valued at $675,000 after buying an additional 335 shares in the last quarter. Sowell Financial Services LLC acquired a new position in shares of argenex in the first quarter worth approximately $332,000. Rakuten Securities Inc. increased its holdings in argenex by 56.4% in the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after purchasing an additional 22 shares in the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in argenex in the first quarter worth approximately $583,000. Finally, Oppenheimer & Co. Inc. increased its holdings in argenex by 10.2% in the first quarter. Oppenheimer & Co. Inc. now owns 915 shares of the company's stock worth $542,000 after purchasing an additional 85 shares in the last quarter. Institutional investors own 60.32% of the company's stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.